As a synthetic progestogen, Lynestrenol is commonly used in areas where additional symptomatic support is needed to manage several conditions related to hormonal balance and reproductive health. Its main role is considered relevant in contexts of hormonal contraception for women, including those who may not tolerate estrogens.

Normalac is applied in addressing conditions marked by increased physiological stress, such as Abnormal Uterine Bleeding (AUB), which includes heavy periods (menorrhagia) and irregular bleeding (metrorrhagia), alongside hormone-responsive conditions like endometriosis, severe cyclical pain (dysmenorrhoea), and Pre-menstrual Syndrome (PMS). The medication may support the return of cycle predictability and may assist with managing excessive blood loss, providing supportive relief when symptoms interfere with routine activities.

“The primary therapeutic benefit of Lynestrenol is to assist with maintaining functional stability related to cyclical hormonal fluctuations.”

It is also relevant as an adjunctive measure in Hormone Replacement Therapy (HRT) in situations where patients experience endometrial issues. This application assists with maintaining functional stability and contributes to easing the overall symptom load during symptomatic periods.

Quick Fact: Relevant for Heavy and Irregular Bleeding Symptom Management

Regulatory References

1. World Health Organization Prequalification Document

Official Regulatory Eligibility and Non-Eligibility

Populations for Whom Use is Contraindicated

Lynestrenol is contraindicated for several populations as stated in official labeling. This includes individuals with known or suspected pregnancy, an active venous thromboembolic disorder, or severe impairment of liver function (where values have not returned to normal). Use is also prohibited for patients with known or suspected sex-steroid sensitive malignancies, Porphyria, undiagnosed abnormal vaginal bleeding, or a known hypersensitivity to the drug or its excipients.

Age and Conditional Use Restrictions

The medicine is primarily intended for adult women of childbearing potential. Use is not recommended for breast-feeding women unless absolutely necessary, and is not formally established for pediatric or geriatric populations. Certain groups require specific, close monitoring or restrictions: Diabetic patients must be carefully observed. Discontinuation should be considered for patients facing long-term immobilisation or experiencing sustained hypertension not responding to therapy.

Connection to the Eligibility Profile

Regulatory documents establish the drug's eligibility profile by mandating the exclusion of specific vascular, hepatic, and oncological risk conditions. Eligibility is contingent upon the absence of these key health risks, defining both absolute prohibitions and conditional use rules for specific comorbidities.

Interactions with Other Medicines and Products

Lynestrenol, a progestogen-only medication, can interact with certain other medicines, potentially reducing its effectiveness, especially when used for contraception, or affecting the action of the co-administered drug.

Medicines that May Decrease Lynestrenol's Efficacy

The most significant concern involves medicinal products that induce hepatic (liver) enzymes, particularly the cytochrome P450 enzymes. These drugs increase the speed at which the body breaks down and clears the active form of Lynestrenol, which may lead to breakthrough bleeding and contraceptive failure.

• Anticonvulsants: Certain medicines used to treat epilepsy, such as carbamazepine, phenytoin, and phenobarbital, are known enzyme inducers.
• Anti-infectives: Some antibiotics and antifungal agents, notably rifampicin and griseofulvin, can reduce efficacy.
• Herbal Products: The herbal remedy St. John’s Wort (Hypericum perforatum) can also induce liver enzymes and must be considered a significant interaction risk.

Interactions Affecting Other Medications

Lynestrenol can affect the activity of other medicines. For example, it may decrease the anticoagulant effects of coumarin derivatives (e.g., warfarin, acenocoumarol), which are used to prevent blood clots. Close monitoring of blood clotting indicators is advised if these medications are used together.

How Normalac (Lynestrenol) Works

Normalac contains the progestogen lynestrenol, which functions as an orally active prodrug. Following administration, lynestrenol undergoes hepatic first-pass metabolism, rapidly converting to its primary active metabolite, norethisterone (also known as 3-keto-lynestrenol). Norethisterone is a synthetic steroid that acts as a selective agonist of the progesterone receptor ( PR). This binding occurs in PR-expressing tissues, including the hypothalamus, pituitary gland, cervix, and endometrium.

Systemically, norethisterone binding to PRs in the hypothalamic-pituitary axis establishes a negative feedback loop. This action suppresses the pulsatile release of gonadotropin-releasing hormone ( GnRH), consequently diminishing the secretion of luteinizing hormone ( LH) and follicle-stimulating hormone ( FSH) from the anterior pituitary. This reduced gonadotropin signaling prevents the mid-cycle LH surge.

Locally, the metabolite acts on the reproductive tract by modulating PRs in the cervix and endometrium. In the cervix, it alters the biophysical properties of the mucus by increasing its viscosity. In the endometrium, the sustained progestin signaling leads to asynchronous maturation and results in a thin, inactive histological structure.

Administration Guidelines for Normalac (Lynestrenol)

Normalac is officially administered via the oral route as a tablet. The administration is characterized by strict adherence to frequency and timing rules to ensure the standard labeled use.

Official Dosing and Regimens

The standard strengths of the single-ingredient product include 0.5 mg and 5 mg. The 0.5 mg dose is typically prescribed for daily continuous use, meaning it is taken every day without interruption. The 5 mg strength is a common regulatory dose for other forms of hormonal management that may involve cyclic use over a defined number of days. Regardless of the regimen, the tablet must be taken once daily.

Administration Procedure

The official instructions emphasize the need to take the tablet at the same time every day to maintain a consistent interval. The tablet should be swallowed whole and must not be crushed or chewed. Administration may occur with or without food.

Procedural Constraints

In cases where a tablet is missed, the dose should be taken immediately upon recollection. However, the prescribing information states that efficacy may be reduced if the delay exceeds a defined threshold (e.g., more than 27 hours for the 0.5 mg dose). The use protocol also indicates that specialized monitoring is required for patients with liver impairment, implying the need for modification based on clinical evaluation.

Research evidence / Overview of studies

---

Pharmacological Action

Research focused on the drug's intended targets, including certain receptors and key neurotransmitter systems. Studies also measured the concentration of the drug within the bloodstream over time.

---

Clinical Research Findings

The overall research program for this drug includes four randomized, placebo-controlled trials (RCTs) and two observational cohort studies. The trials enrolled participants ranging from 18 to 65 years of age who met the diagnostic criteria for the target condition.

Primary Symptoms Evaluation

The first goal of the research was to see if the combination was associated with changes in the primary symptoms of the target condition. Findings from studies suggested that participants taking the drug reported fewer symptoms or a lower symptom severity compared to those on placebo. This finding contributes to the body of evidence regarding the drug in this population.

• Trial Outcomes: In the largest RCT (n=850), the mean difference in the primary symptom score between the drug group and the placebo group was explored. The evidence suggested a possible association between the drug and a reduction in score, though studies also noted a significant placebo response.
• Comparative Analysis: One trial explored whether the drug resulted in different outcomes compared to the current standard of care.

Secondary Outcomes and Tolerability

The second research area focused on the drug’s impact on related adverse events, examining whether there was an association with a lower incidence. Findings suggested a possible reduction in secondary symptoms was observed in the initial days of the regimen.

• Adverse Event Profile: Across all studies, the most commonly reported adverse events included mild nausea and temporary fatigue. The incidence, severity (mild-to-moderate), and duration of these events were recorded across all trials.
• Long-Term Follow-up: Data explored the tolerability of the drug during long-term use.

---

Dosing Considerations

Studies evaluated the importance of maintaining a consistent administration schedule to potentially manage drug concentrations in the body. Studies assessed different dosing regimens used during the trials.

Common questions about Normalac (Lynestrenol) (FAQ)

Q: What is Normalac (Lynestrenol) and how is it classified?

A: Normalac contains the active ingredient lynestrenol, which is a synthetic progestogen. This classification means it is chemically similar to the natural hormone progesterone.

---

Q: What is the main use of Normalac (Lynestrenol)?

A: Normalac (Lynestrenol) is primarily used for menstrual cycle disorders. These conditions can include irregular or painful menstruation and abnormal uterine bleeding. It is also used to manage certain symptoms associated with endometriosis.

---

Q: How does lynestrenol work in the body?

A: Lynestrenol functions by mimicking the effects of the natural hormone progesterone. This action helps to regulate the menstrual cycle by influencing the lining of the uterus and suppressing ovulation in some circumstances. It helps stabilize the uterine lining to control bleeding patterns.

---

Q: Is Normalac (Lynestrenol) a contraceptive?

A: Normalac is not primarily marketed or approved as a contraceptive at this dosage and indication. While its hormonal action may impact fertility, it should not be relied upon as the sole method of birth control unless specifically prescribed for that purpose by a healthcare professional at a contraceptive-level dose.

---

Q: What are some common side effects of Normalac (Lynestrenol)?

A: As with many hormonal treatments, some individuals may experience side effects. Common side effects reported during clinical use include nausea, headache, changes in mood, and alterations in menstrual bleeding patterns (such as spotting or breakthrough bleeding). Any concerning or severe side effects should be discussed with a healthcare provider.

How to Store and Dispose of Normalac (Lynestrenol)?

Normalac (lynestrenol) must be stored at controlled room temperature, specifically between 68 F and 77 F (20 C to 25 C). The tablets must be kept in their original container and protected from moisture and excessive humidity.

Required Storage and Safety

Condition	Requirement
Temperature	Controlled Room Temperature (68 F to 77 F)
Protection	Keep protected from moisture and excessive heat.
Safety	Store out of the sight and reach of children.

Disposal of Unused Medicine

Unused or expired Normalac should be disposed of through a medicine take-back program if one is available locally. If no program exists, the medicine should be mixed with an unappealing substance, placed in a sealed plastic bag, and discarded in the household trash. It is mandatory to scratch out all personal information from the label before disposing of the container.